Further studies should evaluate the concordance of STRAT4 in other special IBC cases, such as those with ERBB2 mutations as well as HER2-low and low-ER cases, as it could provide useful information on biomarker status and patient management. This evidence concerns the gene ESR1 and inflammatory breast carcinoma.